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Research on human subjects in South Africa is guided by the Research Ethics 
Guidelines produced by the National Department of Health, as well as many other 
documents such as the Bill of Rights, the National Health Act and ethical guidelines 
published by the Health Professions Council of South Africa. 
The fundamental issue when considering the ethics of human research is to ensure 
that vulnerable people are protected from exploitation. The ethics of research is 
based on principle-based ethics, which is made up of the principles of autonomy, 
beneficence, non-maleficence and justice. Supporting principles include respect for 
autonomy and the issue of informed consent, scientific integrity, privacy and 
confidentiality. 
Many clinical trials initiated by researchers and/or pharmaceutical companies 
include a genetic component in addition to the main clinical study. The genetic 
component entails the taking and storing of patients’ blood or other tissues for up to 
twenty years, often in a foreign country in a biobank or similar repository. Acquiring 
informed consent for this genetic component of these studies is often problematic, 
in that the exact nature of the research is not always known at the time that the 
samples are taken. In addition the patient may not understand the consequences of 
giving up these samples to various organisations for future experimentation and 
international data exchange and sharing.  
The empirical limb of this study investigated the type of consent given by patients 
for genetic research in studies submitted to the Wits Health Consortium during 
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2013. Additional factors such as length of time and site of storage of the genetic 
samples, as well as data storage and sharing were explored, as well as the 
complexity of the language used for the informed consent. 
Less than a third of the protocols with a genetic component that were studied, 
complied with South African regulations and guidelines governing the obtaining of 
informed consent for genetic research. Recommendations made in order to improve 
this included a standardized informed consent process, attention to the language 
used when obtaining informed consent, the type of informed consent obtained, and 
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This research report is written in the first person, using the Vancouver system for 
referencing. 
The study in this research report arose from my role as a member of the Protocol 
Review Committee (PRC) for clinical trial applications submitted for ethics approval 
by the Human Research Ethics Committee (Medical) of the University of the 
Witwatersrand, through the Wits Heath Consortium Ethics secretariat. The purpose 
of my role on the PRC is to ensure that the facility where the research is being 
conducted is not exposed to additional risk, for example unplanned costs. I became 
intrigued when reading the informed consent forms for storage of specimens for 
future research, including genetic research. There appeared to be an increase in 
these, with many protocols having a genetic component, with variation in the 
amount of information presented. As a result the plan for this current study was to 
perform a two-fold literature review, and a descriptive pilot study of the relevant 
PRC applications approved by the Human Research Ethics Committee (Medical) 
during 2013. 
 
1.1 General remarks 
“The elucidation of the causes of complex diseases pivots on understanding the 
interaction between biological (genetic) and environmental factors that give rise to 
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disease risk. The modest effects of genetic factors in complex diseases supports 
the need for large-scale studies of high-quality human biological materials, paired 
with detailed clinical data, to adequately detect these effects. To this end, human 
tissue biobanks or biorepositories have been developed around the world, by public 
and private entities alike, to provide researchers the opportunity to study collections 
of human biospecimens annotated with clinical and other health-related 
measurements”(1). 
Human tissue biobanks can be considered as “an organized collection of human 
biological material and associated information or data for one or more research 
purposes”(2). These biobanks usually incorporate cryogenic storage facilities for the 
samples, and may range in size, with reference to the number of samples that can 
be stored in the facility. The advantages of using biobank samples for genetic 
research instead of conventional sampling methods for research are as follows: 
 Secure sources of well-stored research material; 
 Unlimited numbers of studies can be performed; 
 Many different disciplines can be involved; 
 Research is less costly; 
 International collaboration and data sharing is enabled. 
However, these major advantages to researchers come at a considerable ethical 
“cost” to the individual donors of genetic material. In addition there are associated 




Research on human subjects in South Africa is guided by the Research Ethics 
Guidelines(3) produced by the National Department of Health. This document is 
informed by various other documents such as the National Health Act(4) and 
Declaration of Helsinki(5). Other guidelines include the Bill of Rights of the 
Constitution of South Africa(6), the National Health Act(4), guidelines for Good 
Clinical Practice(7) and also the ethical guidelines of the Health Professions Council 
of South Africa. International guidelines include the Nuremberg Code(8), the 
Universal Declaration of Human Rights (this has informed section 12 of the South 
African Bill of Rights), and the guidelines of the Council of International Organisation 
of Medical scientists (CIOMS)(9) the Good Clinical Practice (GCP) guidelines(7) 
and the Singapore Statement on Research Integrity(10). The latter is due to be 
updated in the second half of 2015. 
 
1.2 Ethical and legal basis of the research 
The fundamental issue in the context of the ethics of medical research is to ensure 
that vulnerable people are protected from exploitation.  
Ethics of research is based on principle-based ethics(11), which comprises the 
following principles: 
 Autonomy, which deals specifically with the issues of consent and 
confidentiality; 
 Beneficence and non-maleficence, looking at a positive risk-benefit ratio; 
 Justice, which is largely distributive justice, ensuring research subject dignity 
and protection of rights in the context of the greater good. 
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In South Africa we have ethical principles as outlined in the Department of Health 
Ethics in Health Research document(12) that need to be followed, and these 
include the fundamental principles outlined above, with additional supporting 
principles(11), namely: 
 Relevance, indicating that the research needs to be relevant to the individual 
on whom the study is conducted, and also relevant to the community or the 
country(11). 
 Scientific integrity, meaning that the research needs to be based on sound 
science(11). 
 Investigator competence, which embraces integrity as well as competency in 
the research process, by the principal investigator(11). 
 Informed consent, which. is a key factor in human research, indicating 
respect for persons and their rights(11). 
 Privacy and confidentiality, which needs to be respected in terms of an 
individual’s right to protect personal records, as well as the confidentiality of 
the data that is collected.  
 Risks and benefits refer to the risks to the individual, balanced against the 
benefits to both the individual and the community.  
 Justice, which addresses the benefits following on from the research, such 
as post-trial access to drugs.  
 Ethical review by a human research ethics committee needs to be carried out 
prior to all human research. 
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While informed consent is essential in all medical research on humans, a unique 
situation exists in South Africa in that the Constitution entrenches informed consent 
in the Bill of Rights(6). No other country has anything similar. A second important 
consideration is the rapid growth of genetic research in medicine in South Africa 
and the world. 
 
1.3 Problem statement and aim 
The aim of this dissertation is to answer the question: Is the consent obtained from 
adult patients for genetic research informed, morally justified and in keeping with 
South African and International laws, regulations and guidelines? 
 
1.4 Objectives 
The research objectives are: 
• to ethico-legally evaluate the current South African and international laws, 
regulations and professional guidelines governing consent for genetic 
research in adults.  
• to perform a conceptual analysis examining the history and origin of the 
concepts of autonomy and informed consent in law. 
• to retrospectively analyze the type of informed consent given by adults 






1.5 Study design 
A retrospective descriptive research design will be used using research records of 
the Wits Health Consortium (WHC) containing consent for genetic research over a 
period of 1 year. 
 
1.6 Research report outline 
This research report will comprise the following chapters: 
Chapter One: the introduction and a brief summary of the methodology used; 
Chapter Two: an ethico-legal evaluation of the current South African and 
international laws, regulations and professional guidelines governing human and 
human genetic research in adults;  
Chapter Three: a conceptual analysis examining the history and origin of the 
concepts of autonomy and informed consent in law, and their application to human 
genetic research; 
Chapter Four: methodology and results of the empirical limb of the study 
comprising a retrospective review; 










AN ETHICO-LEGAL EVALUATION OF THE CURRENT SOUTH 
AFRICAN AND INTERNATIONAL LAWS, REGULATIONS AND 
PROFESSIONAL GUIDELINES GOVERNING HUMAN AND HUMAN 
GENETIC RESEARCH IN ADULTS. 
 
This chapter will initially describe the various international documents guiding 
research on human subjects, followed by those guiding genetic research. The 
second part of the chapter will discuss the South African laws, regulations and 
guidelines governing human research, followed by those guiding genetic research. 
 
Terms used are: 
 Human tissue research refers to the collection and storage of various types 
of human tissue for the purposes of genetic and other research. 
 Genetic research covers gene therapy, genetic screening and testing, 
patenting human genes and proteins and cloning.  
 Participant is the word used in South Africa, whereas research subject is the 
term used elsewhere. 
Human tissue research and genetic screening and testing will be covered in this 




2.1 International laws, regulations and guidelines 
2.1.1 Human research 
2.1.1.1 Nuremberg Code(8) 
One of the first international ethics documents to be published, (and also the most 
important historically) was the Nuremberg Code(8), which was drawn up in 1947 as 
a result of the Nazi doctors’ trial at the Nuremberg Trials(13, 14), held after the 
Second World War. The Nazi doctors were tried by American judges for crimes 
against humanity, in that they “unlawfully, willfully, and knowingly were principals in, 
accessories to, ordered, abetted, took a consenting part in, and were connected 
with plans and enterprises involving medical experiments, without the subjects' 
consent, upon German civilians and nationals of other countries, in the course of 
which experiments the defendants committed murders, brutalities, cruelties, 
tortures, atrocities, and other inhuman acts”. (13) 
The experiments performed involved the use of high altitude, freezing, malaria, 
mustard gas, bone, muscle and nerve degeneration, bone transplantation, sea 
water, epidemic jaundice, and sterilization.  
The Doctors’ Trial began on the 9th December, 1946 and ended on the 19th July 
1947(14). 
Three American judges presided over the case. 
Sixteen doctors were found guilty; of those 7 were hanged; 5 were sentenced to life 




The Nuremberg Code(8) was drawn up by two medical experts, Leo Alexander and 
Andrew Ivy(14) and unnamed prosecutors who participated in the trials. The Code 
served as a blueprint for today’s ethical principles protecting individuals’ rights in 
medical research.  
The Code(8) mandates the following, with regard to human experimentation: 
 The voluntary informed consent of the human subject is essential. 
 The experiment should yield meaningful results for society, unprocurable by 
other means. 
 The experiment should be designed and based on the results of animal 
studies. 
 The experiment should avoid physical and/or mental suffering and injury. 
 No experiment should be conducted where it is thought that death or 
disablement may occur, unless the experimental physicians are also the 
subjects. 
 The degree of risk must be reasonable. 
 The experiment should be conducted by scientifically qualified persons. 
 During the course of the experiment the subject may withdraw participation. 
 The scientist must be prepared to stop the experiment if it is thought that 
injury, disability or death may occur. 
 
2.1.1.2 Universal Declaration of Human Rights(15) 
The Nuremberg Code was followed in 1948 by the Universal Declaration of 
Human Rights, issued by the General Assembly of the United Nations(15). This 
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document comprises a general preamble, followed by thirty articles, which cover 
a variety of fundamental basic human rights. Article 5 states the following: “No 
one shall be subjected to torture or to cruel, inhuman or degrading treatment or 
punishment.”(15) 
Despite the existence of the Nuremberg Code and the Universal Declaration of 
Human Rights, some researchers continued to exploit vulnerable participants 
and perform unethical research(16). 
 
2.1.1.3 Declaration of Helsinki(17) 
In June 1964 the World Medical Association(WMA) developed the Declaration of 
Helsinki(17) as a statement of ethical principles for medical research on human 
subjects. This is considered a cornerstone document which has influenced 
subsequent legislation and guidelines.  
This publication was much needed, as despite the Nuremberg Code and 
Universal Declaration of Human Rights, patients continued to be exploited for 
research purposes, as was discussed by Henry Beecher in June 1966(16). He 
highlighted numerous studies, where patients did not understand the risks 
involved. In fact some did not even realise that they were participating in an 
experiment. There were many ethical violations in research conducted by 
respected researchers and funding bodies.  
 
The original Declaration(17) has been amended by the World Medical 
Association in 1975, 1983, 1989, 1996, 200, 2004, 2008 and 2013.  
11 
 
The latest version includes the following phrase “including research on 
identifiable human material and data”.(18) 
 
The Declaration of Helsinki is divided into the following sections(18): 
 “Preamble 
 General Principles 
 Risks, Burdens and Benefits 
 Vulnerable Groups and Individuals 
 Scientific Requirements and Research Protocols 
 Research Ethics Committees 
 Privacy and Confidentiality 
 Informed Consent 
 Use of Placebo 
 Post-Trial Provisions 
 Research Registration and publication and Dissemination of Results 
 Unproven Interventions in Clinical Practice” 
 
All of these sections are relevant to different aspects of research involving human 
participants. The section on informed consent is very detailed and specific, and 
serves to protect all categories of patients for various types of research. The 
importance of the individual is emphasized over and above family and community 
members. The type of information that must be given to research participants is also 
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specified, as well as the participants’ right to withdraw at any stage, without any 
ensuing consequences.  
 
2.1.1.4 The Belmont Report(19) 
In 1974 the United States Congress signed the National Research Act into law, 
thereby establishing a National Commission for the Protection of Human Subjects in 
order to develop ethical principles for all research involving human subjects. This 
was triggered by the blatant lack of ethics used during the “shameful” Public Health 
Service Syphilis Study in Tuskegee, Alabama(20). The document that resulted was 
the Belmont Report(19). 
This document highlights the key ethical principles that should guide all clinical 
research, namely: 
 Respect for persons, involving two important ethical principles, namely that 
individuals should be treated as autonomous agents, and secondly that 
those with diminished ability to be responsibly autonomous are protected. 
 Beneficence, ensuring the well-being of research participants. In other 
words, “do no harm”, and maximize the possible benefits. 
 Justice, particularly when deciding who bears the burden of research and 
who receives the benefits. 
 
The Belmont Report applies these principles to the following: 
 Informed consent, with specific reference to information and disclosure, 
comprehension of this information, and voluntariness. 
13 
 
 Assessment of risks and benefits, specifically the nature and scope of these, 
as well as whether they are balanced or in a favourable ratio. This applies 
particularly to vulnerable research subjects. 
 The selection of subjects for the research, ensuring justice in selecting the 
group/community of research subjects, as well as the individuals. 
All of these principles from the Belmont Report(19) should be considered when 
deciding on the ethics of particular clinical research. 
 
2.1.1.5 International Ethical Guidelines for Biomedical Research Involving 
Human Subjects {Prepared by the Council for International Organizations of 
Medical Sciences (CIOMS) in collaboration with the 
World Health Organization (WHO)}(9) 
 
This is the current definitive document on research internationally. The first edition 
was produced in 1982, followed by revisions in 1993 and 2002. The importance of 
these guidelines is that they draw the attention of all those involved in research in 
human subjects to all of the pertinent ethical issues. The 2002 edition makes the 
following comments on the relevance of culture: 
“An issue, mainly for those countries and perhaps less pertinent now than in the 
past, has been the extent to which ethical principles are considered universal or as 
culturally relative—the Universalist versus the pluralist view. The challenge to 
international research ethics is to apply universal ethical principles to biomedical 
research in a multicultural world with a multiplicity of health-care systems and 
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considerable variation in standards of health care. The Guidelines take the position 
that research involving human subjects must not violate any universally applicable 
ethical standards, but acknowledge that, in superficial aspects, the application of the 
ethical principles, e.g., in relation to individual autonomy and informed consent, 
needs to take account of cultural values, while respecting absolutely the ethical 
standards”.(9) 
 
The document is divided into 21 comprehensive guidelines, which include the 
following: 
 Ethical review committees. 
 Ethical review of externally sponsored research. 
 Individual informed consent and obtaining it, as well as the obligations of 
sponsors. 
 Inducement to participate. 
 Benefits and risks of participation, and limitations on risk. 
 Choice of control in clinical trials, and equitable distribution. 
 Research involving vulnerable persons and children. 
 Women and pregnant women as research subjects. 
 Safeguarding confidentiality. 
 Rights of injured subjects to treatment and compensation. 
 Ethical obligations of external sponsors to provide health care services. 
15 
 
These are followed by various appendices, which include research trials 
requirements, the Declaration of Helsinki and an explanation of the phases of 
clinical trials of vaccines and drugs. 
 
2.1.2 Human genetic research 
There are far fewer laws, guidelines and regulations specifically for genetic 
research. 
The following documents make mention of human genetic research. 
 
2.1.2.1 Declaration of Helsinki(18) 
The latest version (2013) of the Declaration of Helsinki includes the following phrase 
in the first sentence of the preamble: “as a statement of ethical principles for 
medical research involving human subjects, including research on identifiable 
human material and data”.(18) This indicates that the entire document applies to 
(but is not limited to) human genetic research as well as research on human 
subjects. 
 
2.1.2.2 International Ethical Guidelines for Biomedical Research Involving 
Human Subjects {Prepared by the Council for International Organizations of 
Medical Sciences (CIOMS) in collaboration with the 




The Introduction section of these guidelines makes the following comment: “Certain 
areas of biomedical research are not represented by specific guidelines. One such 
is human genetics. It is, however, considered in Guideline 18 Commentary under 
Issues of confidentiality in genetics research”(9). 
Guideline 18 states the following under issues of confidentiality in genetics 
research: “An investigator who proposes to perform genetic tests of known clinical 
or predictive value on biological samples that can be linked to an identifiable 
individual must obtain the informed consent of the individual or, when indicated, the 
permission of a legally authorized representative. 
Conversely, before performing a genetic test that is of known predictive value or 
gives reliable information about a known heritable condition, and individual consent 
or permission has not been obtained, investigators must see that biological samples 
are fully anonymized and unlinked; this ensures that no information about specific 
individuals can be derived from such research or passed back to them. 
When biological samples are not fully anonymized and when it is anticipated that 
there may be valid clinical or research reasons for linking the results of genetic tests 
to research subjects, the investigator in seeking informed consent should assure 
prospective subjects that their identity will be protected by secure coding of their 
samples (encryption) and by restricted access to the database, and explain to them 
this process. 
When it is clear that for medical or possibly research reasons the results of genetic 
tests will be reported to the subject or to the subject’s physician, the subject should 
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be informed that such disclosure will occur and that the samples to be tested will be 
clearly labelled. 
Investigators should not disclose results of diagnostic genetic tests to relatives of 
subjects without the subjects’ consent. In places where immediate family relatives 
would usually expect to be informed of such results, the research protocol, as 
approved or cleared by the ethical review committee, should indicate the 
precautions in place to prevent such disclosure of results without the subjects’ 
consent; such plans should be clearly explained during the process of obtaining 
informed consent.”(9) 
These are very specific guidelines and very important in the context of genetic 
research. 
 
2.1.2.3 The Organization for Economic Co-operation and Development (OECD) 
Guidelines on Human Biobanks and Genetic Research Databases(21) 
The Organization for Economic Co-operation and Development (OECD) is a forum 
of 30 democracies who work together to address various issues. South Africa was 
not a member of the committee when they drew up this guidelines document in 
2009.  
 
The guidelines are divided into two sections.  
The first deals with general principles, best practice, establishment of human 
biobanks and genetic research databases (HBGRD) as well as governance and 
oversight/monitoring. This is followed by a detailed discussion of all of the principles 
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involved in the terms of participation in genetic research, such as informed consent, 
as well as the type of informed consent. This is followed by details of the content of 
HBGRDs and the principles and practices involved in the protection of human 
biological material and data. Access, custodianship, intellectual property and 
disposal of materials and data are also dealt with. An important clause pertaining to 
ownership of the genetic material states: “The operators of the HBGRD should have 
a clearly articulated policy and explicitly indicate to participants whether they and/or 
the HBGRD retain any rights over the human biological materials and/or data and 
the nature of such rights.”(21) 
The second section of the guidelines is titled “Annotations”, and basically explains 
statements from the first section, as well as giving examples to clarify various 
issues. 
The annotation on terms of participation is very detailed, explaining the various 
types of consent that may be obtained for genetic research. These will be described 
in detail in Chapter 3 of this research report. 
 
2.2 South African laws, regulations and guidelines 
2.2.1 Human research 
Research on human participants in South Africa is guided by the Research Ethics 
Guidelines(12) produced by the National Department of Health. This document is 
informed by various other documents such as the National Health Act(4) and 
Declaration of Helsinki(17). Two laws include the Bill of Rights of the Constitution of 
South Africa(6) and the National Health Act(4). Additional guidelines that have been 
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produced are the Medical Research Council’s Guidelines on Ethics for Medical 
Research in 2002(22), which pre-dated those of the Department of Health, and also 
the ethical guidelines of the Health Professions Council of South Africa(23). 
 
2.2.1.1 The Bill of Rights of the Constitution of South Africa(6) and the 
National Health Act(4) 
Chapter 2 of the Constitution of South Africa is also known as the Bill of Rights(6), 
and is the supreme law of South Africa. The pertinent sections are paragraph 10, 
which states that “everyone has inherent dignity and the right to have their dignity 
respected and protected”(6), and paragraph 12.2. This covers the right to bodily and 
psychological integrity, which includes the right “to security in and control over their 
body”, as well as “not to be subjected to medical or scientific experiments without 
their informed consent”(6).  
 
Chapter 9 of the National Health Act of 2003(4) deals with the law pertaining to 
human research. Paragraph 71 states the following “Experimentation on a living 
person may only be conducted in the prescribed manner, and with the written 
consent of the person after he or she has been informed of the objects of the 
research or experimentation and any possible positive or negative consequences 





2.2.1.2 The Department of Health (DOH) Ethics in Health Research: Principles, 
Structures and Processes; Research Ethics Guidelines 2004(3) 
The first section of this document deals in detail with the importance of ethics in 
research. This document has many similarities to the Belmont report(19), but with 
additional ethical principles.  
The 3 important principles from the Belmont report(19) are: 
 Respect for persons, which highlights the issue of informed consent, as well 
as privacy and confidentiality. 
 Beneficence, which includes protecting the individual, and incorporates 
minimizing risk and maximizing benefit.  
 Justice, particularly distributive justice, in that the benefits and risks of 
research should be equally distributed amongst the various classes of 
society. 
 
Additional principles specified in the DOH Ethics in Health Research: Principles, 
Structures and Processes; Research Ethics Guidelines 2004(3) include: 
 Relevance: all human research should be relevant to both the individual and 
the greater community involved. 
 Scientific Integrity is an essential component of all research on human 
subjects. 
 Investigator competence and principal investigator responsibilities include 
sensitivity and integrity, as well as competence in performing the research. In 
addition safety monitoring is imperative. 
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 Conflict of interest applies particularly to sources of funding, which must be 
disclosed. 
 Standard of care is described in the DOH Research Ethics Guidelines(3) as 
“the provision of equal standards of medical care to all during research is a 
requirement for demonstrating equal respect for the dignity of research 
participants”(3). 
 Ethical review is a requirement for all human research in South Africa. 
 
The second section discusses Ethics Committees and ethical review in detail. A 
discussion on participants requiring additional attention, such as children, is dealt 
with in great detail. 
The section dealing with human tissue use and genetic research will be dealt with in 
paragraph 2.2.2. 
 
2.2.1.3 Medical Research Council’s (MRC) Guidelines on Ethics for Medical 
Research(22) 
This is a very comprehensive document covering the general principles of ethics in 
medical research. 
The first few sections explain the MRC’s ethics policy, clarify research on humans, 




Section 5 covers the legal and moral justification for research, discussing all of the 
issues pertaining to consent in great detail. This will be dealt with in chapter 3 of this 
research report. 
These sections are followed by the conduct of research, research principles and 
ethical issues in qualitative research. The following two sections look at the 
assessment of the ethics of research and include ethics committees and how they 
function, and also monitoring the conduct of research. The final section covers 
international collaborative research and ethics guidelines for epidemiology. 
 
2.2.1.4 Health Professions Council of South Africa (HPCSA) General Ethical 
Guidelines for Researchers 2008(23) 
This document emphasizes the ethical duties that health researchers have, mainly 
in the context of human research. 
The introductory section deals with various definitions, and as with all of the other 
guidelines, basic ethical principles in health research. 
The duties that are dealt with in the document include the following: 
1. Duties to research participants: 
 Acting in the best interests of research participants; 
 Respect for research participants; 
 Informed consent; 
 Research participant confidentiality; 
 Impartiality and Justice; 
 Health research and medical care; 
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 Potential conflicts of interest. 
2. Duties to research colleagues and other professionals. 
3. Duties to health researchers themselves, which include: 
 Knowledge and skills; 
 Equipment, hygiene and record keeping. 
4. Duties to society, which include: 
 Respect for life; 
 Reporting scientific misconduct; 
 Access to scarce resources; 
 Legal regulations. 
5. Duties to the health care profession, which is basically adhering to the 
guidelines for review processes. 
6. Duties to animals. 
7. Duties to the environment. 
 
2.2.2 Human genetic research 
2.2.2.1 The Department of Health (DOH) Ethics in Health Research: Principles, 
Structures and Processes; Research Ethics Guidelines 2004(3) 
Section 8 and 9 of this DOH document(3) deal with the use of human tissue 
samples and human genetic research. In addition, section 68 of the National Health 
Act(4) makes provision for the Minister of Health to introduce regulations relating to 
tissue, cells, organs, blood, blood products and gametes. Of relevance to this 
research report are the following sentences: 
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“The Minister may make regulations regarding: 
 The production, packaging, sealing, labelling, storage and supplying of 
therapeutic, diagnostic and prophylactic substances from tissue; 
 The supply of tissue, organs, oocytes, human stem cells and other human 
cells, blood, blood products or gametes; the withdrawal of blood from living 
persons and the preservation, testing, processing, supply or disposal of 
withdrawn blood;  
 The acquisition, storage, harvesting, utilization or manipulation of tissue, 
blood, blood products, organs, gametes, oocytes or human stem cells for any 
purpose.”(4) 
 
The DOH guideline(3) also emphasizes that when human tissue is going to be 
used in research, the researchers and the human research ethics committee 
need to be satisfied that the research conforms to both the DOH guidelines(3) 
and the MRC guidelines(24). The latter will be discussed under paragraph 
2.2.2.2. It is also recommended that local research ethics committees draw up 
guidelines to ensure that all research on human tissue conforms to the National 
Health Act(4). 
The fundamental ethical principle that should be taken into consideration when 
performing research on human tissue is respect for persons. The DOH 




 “Provision to the donor of full information about the purposes of the 
sampling and/or an outline of the research proposal; 
 The donor’s consent to the use of the sample in the experiment being 
planned; 
 The donor’s consent to storage and future use of the sample for other 
research; 
 Giving donors the assurance that all secondary use of donated tissue 
samples will require approval of an accredited research ethics committee; 
 Reassuring donors that no tests of known clinical value for diagnosing or 
predicting disease on samples can be linked to them without their 
consent; 
 Provision for appropriate and secure storage of tissue samples; 
 Provision for and maintenance of appropriate and secure systems to 
ensure confidentiality and privacy in the recording, storage and release of 
data; 
 Accountability in the care and usage of samples; 
 A statement of the duration of sample storage.”(3) 
 
Institutional responsibility is highlighted, and includes the following: “It is the 
responsibility of the institution or organization at which research involving human 
tissue samples is conducted, to ensure that all uses of human tissue samples are in 
accordance with the consent given by the donors.”(3) Proper detailed records must 
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also be kept. Samples that are not needed anymore should be disposed of “safely 
and sensitively.”(3) 
Human tissue repositories are discussed, and described as having 3 components: 
1. “Collection of samples; 
2. Storage and data management in an appropriate repository; 
3. Investigation of recipients.”(3) 
All of these functions need to be strictly overseen by a research ethics committee. 
Human genetic research generates ethical issues unique to this type of research; 
namely the fact that although genes are personal, they are not unique to one 
individual, and are shared with family members. This has many ramifications for the 
individual concerned, the blood relatives, and the non-blood relatives such as 
partners and spouses. There are potential social and cultural consequences of 
genetic research and the results that may be produced, as well as life-changing 
decisions if certain genetically-linked disease states are unearthed.  
 
The ethical issues pertaining to human genetic research are as follows: 
 Privacy and confidentiality of the stored genetic information or research 
results. The research protocols need to specify whether genetic information 
or genetic material, and any information derived from them will be stored in a 
potentially identifiable format, or whether they will be de-identified at all 
times. As with the CIOMS guidelines, the research results may not been 
released to the family without the individual’s informed consent.  
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 Informed consent and waiver of consent under certain circumstances. These 
will be dealt with in chapter 3 of this thesis. Genetic counselling must be 
offered to individuals who consent to the use of their genetic material and 
information for future research, as this may have unanticipated 
consequences. 
 
2.2.2.2 Medical Research Council (MRC) Guidelines on Ethics for Medical 
Research: Reproductive Biology and Genetic Research(24) 
This is a very comprehensive booklet which deals with the ethical issues pertaining 
to genetic screening and testing, gene therapy and cloning. 
Gene therapy, genetic testing and cloning are not in the scope of this research 
report, but the ethical issues pertaining to genetic screening fall under human tissue 
and genetic research. 
 
Genetic screening may be divided into three phases from the process point of view. 
This is useful when examining the ethical aspects. They are: 
1. Preparation of the participant or patient, which centres around informed 
consent. 
2. Analysis of the genetic material, during which phase one needs to consider 
adequacy of procedure and confidentiality. 
3. Interpretation of the analysis coupled with ensuing support programmes. This 
may involve the management of the findings and the impact they may have 




Screening programmes for various cancers and chronic diseases that may have a 
genetic basis are currently the most commonly performed genetic screening in 
adults in South Africa. 
As has been discussed, genetic counselling is an important aspect of genetic 
screening. There are numerous ethical principles involved as follows: 
 Respect for participants and their families, as well as their decisions, 
“according to the principles underlying informed consent”(24); 
 “Preservation of family integrity”(24); 
 Full, honest and unbiased disclosure. This may prove difficult at times, if a 
totally unexpected result is found; 
 Protection of privacy of the participant and family; 
 Informing individuals that it is their ethical duty to disclose possible genetic 
risks to blood relatives and moral duty to the public if relevant to their safety. 
(This should perhaps be included in the initial informed consent in the 
preparation for screening?); 
 To observe “the duty to re-contact if appropriate and desired”(24). 
 
At times it may be felt that clinicians are placed in a difficult situation knowing the 
results of a genetic screening test. There is no law in South Africa that dictates that 
a clinician may disclose results to other parties such as family members, unless 
consented to by the participant. Privacy and confidentiality must be maintained at all 
times. There may be exceptional circumstances when non-disclosure may have 
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serious consequences. It is advised that even in these situations a serious attempt 
must be made to obtain the participant’s consent to disclose findings to other family 
members. 
As can be seen, in contrast to many countries, South Africa has very detailed laws, 
guidelines and policy statements on the issues pertaining to human genetic 
research, particularly the ethical principles involved. An area of concern is the 
complex issue of data sharing. There is a lack of a section dealing with this in the 



















A CONCEPTUAL ANALYSIS OF AUTONOMY AND INFORMED 
CONSENT 
 
Autonomy and respect for autonomy are key ethical principles involved when 
analyzing and understanding informed consent. These will be outlined and 
discussed, particularly in the South African context of human genetic research. 
 
At the outset, it is important to note that irrespective of patients’ legal and ethical 
right to autonomy, doctors have an ethical and legal duty of care to their patients. 
Strauss(25), the doyen of medical law in South Africa, gives the following example 
to clarify this: “when performing an operation or treating a patient, the procedure 
should be so executed with such professional skill as to avoid injuring the patient. 
Failure to do so amounts to a delict (civil wrong), entitling the patient to claim 
damages. Liability of a doctor to a patient is, therefore, not dependent on the 
existence of a contract between the parties or on the patient having given consent 
to undergo treatment”(25). 
 
3.1 Autonomy 
The following was stated by Isaiah Berlin in 1969: “I wish my life and decisions to 
depend on myself, not external forces of whatever kind. I wish to be the instrument 
of my own, not of other men’s acts or will. I wish to be a subject, not an object: to be 
moved by reasons, by conscious purposes, which are my own, not causes which 
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affect me, as it were from outside. I wish to be somebody, not nobody: a doer – 
deciding, not being decided for, self-directed and not acted upon by external nature 
or by other men as if I were a thing, or an animal, or a slave….I wish, above all, to 
be conscious of myself as a thinking, willing, active being, bearing responsibility for 
my choices and able to explain them by references to my own ideas and 
purposes”(26). 
 
This epitomizes the exact meaning of autonomy, which is derived from two Greek 
words, autos, meaning self, and nomos, to rule. In other words, autonomy means to 
rule oneself, and to therefore make one’s own decisions. “Autonomous actions are 
the outcome of deliberations and choices by rational persons in the moral 
sense”(27). When applied to healthcare, this means that once a patient is supplied 
with all of the relevant information, he or she is entitled to make the final decision on 
the treatment that has been recommended, even though the healthcare practitioner 
may not agree with the patient’s final decision. 
 
The Roman law maxim “volenti non fit iniuria”(28), means if someone consents, 
then no harm can be done to that person. These are the original legal grounds of 
consent. However, ethically, doctors always relied on their own judgment about their 
patients’ need for information and medical care, as long as the ethical principles of 
beneficence and non-maleficence guided this. Hence the paternalistic approach by 
many health care practitioners to patients’ medical needs. In the mid twentieth 
century together with various civil rights movements and moves for social reform, 
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people and patients started demanding rights to information and the freedom to 
make informed choices and decisions. 
 
The ethical principle of patient autonomy in South African medical law was judicially 
recognized in 1923 in the case of Stoffberg v Elliot(25). The judge instructed as 
follows: “In the eyes of the law every person has certain absolute rights which the 
law protects. They are not dependent on statute or contract, but they are rights to 
be respected, and one of the rights is absolute security to the person. Any bodily 
interference or restraint of man’s person which is not justified in law, or excused in 
law or consented to is a wrong, and for that wrong the person whose body has been 
interfered with has a right to claim such damages as he can prove he has suffered 
owing to that interference. A man, by entering a hospital, does not submit himself to 
such surgical treatment as the doctors in attendance upon him may think 
necessary; he may submit himself for medical treatment, but I am not going into 
that; I am not going to attempt to define the exact limits of the medical treatment, 
because they do not seem to me to be material in this case, but he does not 
consent to such surgical treatment as a doctor may consider necessary. By going 
into hospital, he does not waive or give up his right of absolute security of the 
person; he cannot be treated in hospital as a mere specimen, or as an inanimate 
object which can be used for the purposes of vivisection; he remains a human 
being; and he retains his rights of control and disposal of his own body; he still has 
the right to say what operation he will submit to, and, unless his consent to an 
operation is expressly obtained, any operation performed upon him without his 
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consent is an unlawful interference with his right of security and control over his own 
body, and is a wrong entitling him to damages if he suffers any”(28). 
Thus as far back in the early 1920’s in South African law, patients have had a legal 
right to autonomy. 
This was followed by the case of Castell v de Greef(29) in 1994. This is considered 
to be the landmark case with a definitive ruling on how much needs to be disclosed 
to the patient in terms of informed consent, thus re-emphasizing the importance of 
patient autonomy. In this case it was judged that for consent to be informed, a 
patient needs to fully appreciate the nature and extent of the harm or risk to which 
he or she is consenting. This is referred to as material risk, which means a risk that 
a reasonable person would consider significant. If applied to anaesthesia, an 
example would be the complication of paraplegia following spinal anaesthesia. 
Although rare, this would be considered a material risk. Likewise if applied to human 
research, a severe drug reaction, although rare when taking certain drugs, would be 
considered a material risk and would warrant disclosure to the participant. 
 
The interpretation of material risk has been considered too vague, in the legal world. 
The HPCSA ethical guidelines booklet on informed consent(30) uses similar 
terminology, quoted from Castell v de Greef, without specifically explaining material 
risk. In Castell v de Greef(29) the “reasonable doctor test” was also discussed. 
However, this leaves the determination of the doctor’s obligation or duty in the 
hands of the medical profession. Judge Ackermann concluded that the focus 
needed to change from a doctor-centred approach to a patient-centred approach. 
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He stated: “it is clearly for the patient to decide whether he or she wishes to 
undergo the operation, in the exercise of the patient’s fundamental right to self-
determination”(31). Thus the principle of patient autonomy was upheld. 
However, this right to self-determination cannot be fully exercised if the patient is 
not given the correct and sufficiently detailed information.   
 
Thomas aptly wrote in his article on the lessons learnt from this case: “The 
subsequent adoption of the Constitution and entrenchment of the rights to dignity 
and bodily integrity highlight that South African society is currently founded on the 
underlying values of individual autonomy and self-determination. Indeed, section 
12(2)c of the Constitution expressly requires informed consent for certain medical 
procedures(6). The National Patients’ Rights Charter, issued in 2001 by the 
Department of Health, and the National Health Act 61 of 2003(4) both seek to give 
effect to these values”(31). 
However, once again the degree of disclosure in informed consent was not fully 
explained. 
 
3.2 Respect for Autonomy 
Beauchamp and Childress(32) proposed the following rules, when considering 
respect for autonomy: 
 “Tell the truth. 
 Respect the privacy of others. 
 Protect confidential information. 
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 Obtain consent for interventions with patients. 
 When asked, help others make important decisions”. 
Moodley makes the point that “these rules and the principle of respect for autonomy 
are not absolute, but rather prima facie. A prima facie rule refers to one that must be 
fulfilled unless it conflicts on a particular occasion with an equal or stronger 
rule”(33). 
 
On the basis of these rules we therefore are obliged to indicate our respect for 
autonomy in the following ways: 
 Obtain informed consent; 
 Confidentiality; 
 Truth telling; 
 Communicate effectively. 
 
The HPCSA has produced a document entitled “General ethical guidelines for the 
health care professions(34)”. Section 2 lists the core ethical values required of 
health care practitioners. They include the following: 
 Respect for persons; 
 Best interests or well-being: non-maleficence; 
 Best interests or well-being: Beneficence; 
 Human rights (recognition of); 
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 Autonomy: “Health care practitioners should honour the right of patients to 
self-determination or to make their own informed choices, and to live their 
lives by their own beliefs, values and preferences”. 
 Integrity, truthfulness, compassion and tolerance; 
 Confidentiality; 
 Justice; 
 Professional competence and self-improvement; 
 Community. 
 
Section 4 deals with duties of health care practitioners, describing a duty as an 
obligation. Duties are described as being ethical, legal (duties imposed by common 
and statute law) or both, and form part of their personal, social, professional and/or 
political lives. 
 
3.2.1 Informed consent as applied to medical treatment 
Carstens and Pearmain in their book Foundational Principles of South African 
Medical Law stated the following in the chapter on grounds of justification for 
medical interventions and other defenses in medical law(28): “Informed consent is 
undoubtedly the foundation or core of the patient / doctor relationship, emanating 
from the law of obligations and underscored by ethical considerations”.  
The application of the doctrine of informed consent is often controversial, because 
of the understanding and perceptions associated with the doctrine, and the fact that 
many health care practitioners are not very comfortable with it. In addition, decisions 
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in courts on the issue appear inconsistent. However, once the doctrine of informed 
consent was incorporated into our South African law, it necessitated a paradigm 
shift from medical paternalism to patient autonomy. This is exactly what Judge 
Ackermann stated in Castell v de Greef(29). 
 
One of the fundamental issues that was highlighted in this case was the degree of 
disclosure required in order for consent to be informed to allow for full patient 
autonomy.   
If one considers the law of contract, (which is what the informed consent agreement 
is considered in law), the following holds: 
 “The patient’s consent will be obtained with regard to treatment that is 
administered to him or her prior to the administration of such treatment; 
 The provider undertakes to render the health services in accordance with the 
patient’s consent and on the basis of the information supplied to the patient 
in order to obtain that consent”(28). 
 
In Oldwage v Louwrens(28) in 2004, Judge Yekiso found that the plaintiff had not 
been given sufficiently detailed information in order for the consent for surgery to 
have been informed, and that this constituted a violation of the plaintiff’s right to 
bodily and psychological integrity, and was therefore assault. This decision was 





Informed consent has been described as a process, consisting of the following 
elements(32): 
 “Threshold elements: Competence to understand and decide, and 
voluntariness in deciding. 
 Information elements: Disclosure of a plan, recommendation of that plan and 
understanding the information and plan. 
 Consent elements: Decision against or in favour of the plan, and 
subsequently authorising it”. 
In 1991, prior to the advent of our South African Constitution and National Health 
Act, Strauss simplified the process, and proposed “four golden rules(25)” for 
obtaining informed consent: 
 “Obtain consent from the person legally competent to give consent; 
 Obtain informed consent; 
 Obtain clear and unequivocal consent; 
 Obtain comprehensive consent.” 
The current HPCSA guidelines include all of these. 
 
The HPCSA has published guideline booklet 9, titled: “Seeking patients’ informed 
consent: the ethical considerations(30)”.  This is a comprehensive document, which 
highlights the essential components when seeking informed consent from patients. 
These are based on ethics and South African law. 
 
The following components of informed consent are discussed: 
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 Provide the patient with sufficient information, as is laid down in the National 
Health Act(4). The following needs to be disclosed to patients: 
 “Their patient’s health status except in circumstances where there is 
substantial evidence that the disclosure of the patient’s health status 
would be contrary to the best interests of the patient; 
 The range of diagnostic procedures and treatment options generally 
available to the patient; 
 The benefits, risks costs and consequences generally associated with 
each option; and 
 The patient’s right to refuse health services and to explain the 
implications, risks and obligations of such refusal. 
 Patients have a right to information about any condition or disease 
from which they are suffering. This information should be presented in 
a language that the patient understands and in a manner that takes 
literacy into account”.  
 The issue of withholding information is discussed in detail, referring to 
significant risks as material risks. Of relevance is the following paragraph: 
“Health care practitioners should not withhold information necessary for 
decision making unless they judge that disclosure of some relevant 
information would cause the patient serious harm. In this context, serious 
harm does not mean that the patient would become upset or decide to refuse 
treatment.” 
 The consent must be comprehensive, exploring all possible eventualities. 
40 
 
 It is recommended that the health care practitioner obtains the consent, but if 
this task is delegated, it must be delegated to someone who acts in 
accordance with the HPCSA booklet 9. 
 Health care practitioners must ensure voluntary decision-making, and not 
superimpose paternalistic consent-giving, incorporating whatever the 
practitioner thinks that the patient should decide. 
 
These excerpts from the National Health Act(4) and the HPCSA guidelines(30) are 
more specific than Castell v de Greef(29) in the extent of disclosure that is required, 
in order for consent to be informed. 
In addition, the guidelines emphasise that the process of informed consent can only 
occur between a health care practitioner and an adult patient (older than 18 years) 
who has the mental capacity to give consent.  
 
3.3 Autonomy and respect for autonomy as applied to human research  
Research on human subjects in South Africa is guided by the Research Ethics 
Guidelines(12) produced by the National Department of Health. This document is 
informed by various other documents such as the National Health Act(4) and 
Declaration of Helsinki(18). Other guidelines include the Bill of Rights of the 
Constitution of South Africa(6), the National Health Act(4), guidelines for good 
clinical practice(7) and also the ethical guidelines of the Health Professions Council 




The fundamental issue when looking at the ethics of human research is to ensure 
that vulnerable people are protected from exploitation.  
Ethics of research is based on principle-based ethics(11), which comprises the 
following principles: 
 Autonomy, which deals specifically with the issues of consent and 
confidentiality; 
 Beneficence and non-maleficence, looking at a positive risk-benefit ratio; 
 Justice, which is largely distributive justice, ensuring research subject dignity 
and protection of rights in the context of the greater good. 
 
In South Africa we have ethical principles as outlined in the Department of Health’s 
Ethics in Health Research document(12) that need to be followed, and these 
include the fundamental principles outlined above, with additional supporting 
principles(11), namely: 
 Relevance, indicating that the research needs to be relevant to the individual 
on whom the study is conducted, and also to the community or the 
country(11). 
 Scientific integrity, meaning that there needs to be sound science as the 
basis of the research(11). 
 Investigator competence, which embraces integrity as well as competency in 
the research process, by the principal investigator(11). 
 Informed consent, which. is a key factor in human research, indicating 
respect for persons and their rights(11) 
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 Privacy and confidentiality, which needs to be respected in terms of an 
individual’s right to protect personal records, as well as the confidentiality of 
the data that is collected(11). 
 Risks and benefits refer to the risks to the individual, balanced against the 
benefits to both the individual and the community(11). 
 Justice, which addresses the benefits following on from the research, such 
as post-trial access to drugs(11). 
 Ethical review by a human research ethics committee needs to be carried out 
prior to all human research(11). 
 
3.3.1 Informed Consent for human research 
“Informed consent in the context of medical research and human experimentation is 
now firmly entrenched in section 12(2)c of the Constitution of South Africa(6), which 
states that everyone has the right to bodily and psychological integrity, which 
includes the right not to be subjected to medical research or scientific experiments 
without his or her informed consent”(28). In addition, chapter 9 of the National 
Health Act(4) deals with the issues pertaining to informed consent for research on 
human subjects. 
 
With reference to the DOH principles(3), the process of informed consent and 
confidentiality indicating respect for the autonomy of the research subject is often 
treated superficially, but is in fact one of the cornerstones of research. In addition, 
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the issue of disclosure is fully described, in comparison with the disclosure for 
consent for medical treatment alluded to in the National Health Act(4).  
 
The process of informed consent involves the following(11): 
 Full and prior disclosure of all aspects of the research (how it differs from 
clinical practice, nature, duration and purpose) to the research participant, 
including possible risks and benefits. Other aspects of the study that need to 
be discussed are reimbursement or compensation (if any), and whether or 
not the participant will have access to the treatment or intervention 
afterwards. In addition, the participant needs to understand that he/she may 
withdraw from the study at any time. 
 Total confidentiality and the means by which this will be maintained, and 
whether there is any potential breach of confidentiality. For example, all 
personal identifiers such as name, identity number, address, date of birth and 
others must be protected. 
 The process of obtaining informed consent must entail full understanding of 
the proposed research, including all questions being fully answered by the 
researcher in a manner and language understood by the participant. As is 
stated in the CIOMS(35) guidelines, “the investigator must bear in mind that 
the prospective subject’s ability to understand the information necessary to 
give informed consent depends on that individual’s maturity, intelligence, 
education and belief system. It also depends on the investigator’s ability and 
willingness to communicate with patience and sensitivity”. Britz and le Roux-
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Kemp highlight this issue in their article in the South African Medical 
Journal(36) by stating: “A once-off meeting with the researcher may be 
insufficient for the prospective participant to comprehend the research, since 
informed consent requires sufficient time for understanding. Language 
barriers are common in a culturally diverse country like South Africa. Ethically 
and legally the language used to discuss informed consent must be one that 
participants choose and feel comfortable with”. 
 Informed consent needs to be totally free and voluntary. As is stated in the 
South African Department of Health Research Ethics guidelines(12), 
“consent may not be induced by fear, force, threats, duress, coercion, 
compulsion, deceit, fraud, undue influence, perverse incentives or financial 
gains”. 
 Research participants must have the capacity to give informed consent. In 
South Africa, the Bill of Rights of the Constitution(6) states that capacity from 
the age point of view is 18 years. Capacity also entails being of sound mind. 
Special guidelines are also in place for research that is being performed as 
part of emergency treatment(12) in an individual who would have capacity 
under normal circumstances. 
 
Another issue that also warrants discussion when considering informed consent of 
research participants is that some of the challenges to the research process in the 
context of multi-centre studies must be declared. These are parameters such as the 
cultural environment of the participant, the socioeconomic context of the participant, 
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participant vulnerability and therapeutic misconception. The latter is common, where 
the research participant believes that the purpose of the clinical trial is to benefit the 
patient rather than the acquisition of data for scientific knowledge. 
 
Finally, when dealing with informed consent, there is the issue of deception of 
participants, of concealment or of covert observation. The South African 
Department of Health guidelines(12) state that “ as a general principle, deception of 
identifiable participants, concealment of the purposes of research or covert 
observation are not considered ethical because they are contrary to the principle of 
respect for persons and the obtaining of informed consent”. There are 
circumstances, however, such as in studies of human behaviour, where 
concealment is necessary. Under these circumstances, special criteria need to be 
fulfilled(12). 
 
3.3.2 Research vulnerabilities 
The issue of research vulnerability falls into the domain of respect for autonomy, 
when one examines human research. This discussion is particularly pertinent in the 
South African context(11). All participants in research studies need to be protected 
against exploitation and other forms of harms, and those who fall into the vulnerable 
groups need additional protection as per the CIOMS guidelines(35). 
 
There are six categories of vulnerability, which are as follows(11): 
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1. Cognitive, which describes an individual’s ability (or lack thereof) to freely 
give consent to participate in a study. Some of these considerations have 
already been alluded to. There are 4 types of cognitive vulnerability, which 
include: 
 People not of sound mind (dementia, other mental illness, mental 
retardation); 
 Children, which is defined as being less than 18 years of age; 
 Adults undergoing emergency treatment which is part of a research 
study; 
 Participants with language barriers, who may not fully understand the 
research. 
2.  Juridic vulnerability, which describes the investigator authority or power over 
the research participant, limiting the participant’s ability to give proper 
informed consent. Potential participants referred to in this group include 
government officials, prisoners, military personnel, students, institutionalized 
people and similar, all of whom may feel pressurized into participating. 
3. Deferential vulnerability, which is a type of vulnerability where participants 
feel obligated to participate because of cultural or social norms or pressures. 
An example of this is a cultural environment where a woman feels obligated 
to participate in order to please her husband. Community leaders are often 
able to assist in these circumstances. 
4. Medical vulnerability, where the research participant may be desperate for 
treatment for a certain condition, such as cancer or HIV/Aids, and may have 
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a “therapeutic misconception” about the value of the actual research itself. A 
subgroup of medical vulnerability is research on foetuses. In South Africa this 
may only be performed(12) if the research is of minimal risk to foetus and 
mother. In addition, both parents must be legally competent and have 
already given informed consent.  
5. Allocational vulnerability, which often arises in disadvantaged population 
groups, where individuals may feel pressurized to participate because of 
social or financial distress. The incentives offered to participate in the 
research may appear as help to alleviate this. There is a grave concern 
about unfair exploitation in this population group. 
6. Infrastructural vulnerability, which occurs when there are inadequate 
resources in a community to carry out the research. Examples of this are the 
requirement for a telephone, for electricity, or for access to a health care 
centre which may be some distance away. 
 
In addition to individual vulnerabilities and potential harms, socially vulnerable 
groups or communities may be adversely harmed as a result of the research itself, 
or possibly the dissemination of the results of the research. These “group” harms 
can include physical, economic, social (stigmatization), legal and psychological 
damages. Prior to conducting research studies that have the potential to cause 
harm to a group or community, it is advised to consult with the community 




3.4 Autonomy and respect for autonomy as applied to human genetic 
research  
The general ethical considerations which apply to research in human participants 
apply equally to human genetic research. However, there are additional ethical 
considerations, (of which the first four apply to autonomy), which include the 
following(11):  
 Concerns about discrimination/stigmatization of  individuals and 
communities; 
 Patenting and the consequent commercial interest may retard or confine 
“discoveries” from the research point of view; 
 Reducing human beings to their DNA sequence may have serious and 
disparate consequences. The research may yield important information for 
family members which may have legal, moral, social and biological 
consequences. The results may even be useless, with the research causing 
unnecessary stress and anxiety. Unrelated family members such as spouses 
may have an additional interest because the results may ultimately involve 
offspring;  
 The possible lack of respect of values, traditions and the integrity of families 
and individuals, with a total lack of involvement of the community; 
 The ethical principle of justice plays a key role in the following ways: 
 “Compensatory justice, meaning that the individual, group or 
community should receive fair compensation for contribution/s; 
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 Procedural justice, whereby the decisions that are made about benefit 
sharing are impartial and exclusive; 
 Distributive justice, meaning that there needs to be equitable 
allocation and access to resources”. 
 Benefit sharing in a variety of ways which include therapeutic, monetary, 
capacity building and new information generation(11). 
 
3.4.1 Informed consent for human genetic research 
When one considers human genetic research, one needs to apply these same 
aforementioned ethical principles. Once again the process of informed consent 
(from the individual, the family or community) is a vital ethical component, which 
raises many concerns and unanswered questions at this time. 
From the point of view of informed consent, the whole issue of individual autonomy 
and confidentiality needs to be re-visited, as tissue and genetic research often 
extends beyond the genes of one individual research participant. Where others, 
such as family or a cultural group are involved each research participant needs full 
disclosure, confidentiality, understanding and appreciation, voluntariness and 
capacity, as has been discussed previously. 
Genetic research requires a whole different mindset. 
The differences arise with the manner in which the biological samples are taken and 




 “Those obtaining the samples may be intermediaries who are not involved in 
the actual research; 
 The samples stored can be used for a multitude of different research studies. 
This includes future studies which cannot necessarily be specified at the time 
of taking the sample; 
 Whether or not samples are identifiable is a key factor: 
 If research results are disclosed with identifiable samples it is an 
invasion of the donor’s privacy, unless the donor has given permission 
for this. This could lead to stigmatization and genetic discrimination; 
 If unidentifiable samples are used, the research may be such that the 
donor would not approve of it for cultural, religious or moral reasons”. 
A simple example is stigma that might be attached to a community; for 
example Huntington’s chorea. 
 
The issue of informed consent in this environment is very problematic in terms of 
conventional informed consent for conventional human research. As has been 
alluded to previously, protecting patient autonomy is crucial, but at the same time 
genetic research is supposed to be for the greater societal good. With genetic 
research one has to ask the question: “Is it really possible to obtain proper informed 
consent?” or is it just permission, with disregard for patient autonomy, accompanied 




The expert conference that was held in Cape Town in December 2012 to discuss 
changes that are needed in the Declaration of Helsinki(5) discussed the issue of 
consent for genetic research, amongst other issues. Tasse et al in the European 
Journal of Human Genetics(38) discussed various solutions to the problem of 
informed consent, particularly with retrospective access to data. 
 
Kirchhoffer and Dierickx in an article on consent for tissue and genetic research(39) 
emphasized the importance of human dignity (as is enshrined in our South African 
Constitution(6)) when considering guidelines for informed consent and genetic 
research. The National Health Act(4) reiterates that health legislation must take into 
account section 10 of the Bill of Rights of the Constitution(6), which emphasizes the 
need to respect and protect people’s dignity. Chapter 9 of the National Health Act of 
South Africa therefore insists that informed written consent be given prior to 
research on human subjects.  
 
Human tissue biobanks 
For purposes of clarity, human tissue biobanks can be considered as “an organized 
collection of human biological material and associated information or data for one or 
more research purposes”(2). These biobanks usually incorporate cryogenic storage 
facilities for the samples, and may range in size, with reference to the number of 
samples that are able to be stored. The advantages of using biobank samples for 




 Secure sources of well-stored research material; 
 Unlimited numbers of studies can be performed; 
 Many different disciplines can be involved; 
 Research is less costly; 
 International collaboration is enabled. 
However, as with many things in life, these major advantages to researchers come 
at a considerable ethical “cost” to the individual donors of genetic material. In 
addition, there are associated legal and social issues, which are being grappled with 
all over the world. 
 
Kirchhoffer and Dierickx(39) further emphasize that there are features of biobanking 
that might lead people to refuse to be involved in biobank research on the basis of 
human dignity in the following circumstances: 
 Biobanking cannot guarantee what type of research the samples will be used 
for in the future. There is no guarantee that the research results will not be 
used for malicious or profit orientated purposes, resulting in possible genetic 
discrimination; 
 Biobanks store human tissue and genetic material, and for religious reasons 
(being created in the image of God), people may feel that biobank research 
is an affront to dignity; (This is a personal opinion) 
 Biobank research may receive opposition because it could be the basis for a 
trade on body parts or body tissues, the latter being closely governed by our 
National Health Act(4); 
53 
 
 Of particular interest is the use of biobanks for the storage of stem cells, 
which “contribute to innate healing and harbour a promising role for 
regenerative medicine. Stem cell banking through long-term storage of 
different stem cell platforms represents a fundamental source to preserve 
original features of stem cells for patient-specific clinical applications”(40). 
Apart from opening up fantastic opportunities for medicine, healing and 
research, this also lends itself to possible abuse and exploitation, with stem 
cells being punted at huge cost as a possible elixir to immortality.  
 
This research report will discuss human genetic research, specifically pertaining to 
human tissues and genetic screening and testing, including samples stored in 
biobanks or other similar human tissue repositories. 
How then, in the context of South Africa, with our Bill of Rights and our National 
Health Act, are we going to manage to obtain informed consent with full disclosure 
in human genetic research? 
 
Various authors have suggested the following possible solutions to the consent 
issue(38, 39): 
 Broad or blanket consent, which would allow the use of a sample for genetic 
research in general, including future unspecified projects. New consent 
would then be necessary if the next research project differs from the wide 
ambit of the original. From the perspective of human dignity, the case for 
broad consent “explicitly acknowledges the existential importance of being 
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able to decide on morally meaningful matters for oneself. In addition the 
belief that one can contribute to the good of others plays a role”(39); 
 Multilayered or tiered consent, with secondary use as another alternative. In 
this case a comprehensive consent form is used, allowing the genetic sample 
owner to choose from a number of options in advance, as well as specific 
research domains. The latter is covered by a “secondary use statement”. 
This form of consent has been described as costly and complex; 
 Presumed consent, where opting out is a totally different approach to 
informed consent, and is currently in use in some developed countries. 
Samples are banked for research because it is believed that the donors of 
the samples would be satisfied with this. There is an accompanying “opt out” 
clause, and ethically this form of consent is justified by “participating for the 
good of the dignity of everyone in the population”(39); 
 Re-contact/re-consent, which is very costly and labour intensive. It may also 
be seen as an invasion of privacy, having to be recontacted for every new 
study. Nevertheless, it probably fulfils the criteria of fully informed consent 
with disclosure. 
 Waived consent has been introduced by some Research Ethics Committees 
where re-contact consent has been impossible. Strict criteria need to be 
applied in these circumstances in order to prevent abuse. 
 Recently the concept of Dynamic consent was introduced by a research 
group at Oxford University(41). It entails “an interactive personalized 
interface that allows participants to engage as much or as little as they 
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choose and to alter their consent choices in real time. It allows the same 
samples/information to be (re)used with the knowledge and consent of the 
individual, enabling him/her to give and revoke consent to the use of their 
samples and information in response to their changing circumstances”.(41) 
This form of consent is not paper based, but uses a technology-based 
platform, and is probably the only type of consent that takes into account full 
disclosure, as well as the option to revoke the consent in real time. 
 
The literature is seemingly unanimous in allowing tissue sample donors to withdraw 
their consent and their samples at any time. This raises another ethical issue in that 
this is not always possible, as samples are exchanged and data are sent all over 
the world. In addition, samples may undergo transformation into specific cell lines, 
which can also be duplicated and exchanged. This challenges the supremacy of 
consent, autonomy and human dignity. 
 
Other ethical and legal issues that require consideration for consent in genetic 
research are as follows: 
 Confidentiality is the predominant ethical concern with regard to identifiability. 
When giving consent, tissue sample donors need to understand the concept 
of identifiability and the different levels of anonymisation of samples.  
 Anonymity of the individual does not always guarantee anonymity of the 
group or community. There are different levels of anonymity, which seem to 
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be a non-exhaustive list of terms(42), such as anonymised, de-identified and 
coded, which the donor needs to understand, as part of the consent process.  
 Benefit sharing is a reality associated with genetic research. It includes the 
sharing of information, licensing, capacity building and the sharing of 
financial benefits. Benefit sharing agreements need to be drawn up before a 
study begins, particularly where huge multinationals may be involved with the 
potential for exploiting vulnerable groups or populations. In addition, the 
benefit sharing must be bidirectional, with both parties benefiting, in the 
following potential areas: 
 Information sharing, particularly informing the research participants of 
important scientific discoveries; 
 Sharing information from the study, only if there is clinical benefit, 
preferably with the donor’s own doctor involved (with the donor’s prior 
consent); 
 Financial benefits need to be shared, and this must be decided on in a 
binding legal agreement beforehand. 
 
An important issue that has not been explored when considering ethical and legal 
issues in genetic research is that of closure of the facility where human genetic 
tissue is stored(11). May one sell the tissue samples? May one destroy them? Does 
one need to contact the donors of the samples? If the donors have died, may the 
family make the decisions concerning the samples? These are all important issues 
impinging on autonomy and informed consent. 
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3.4.2 South African guidelines on informed consent for genetic research 
As discussed in chapter 2, the DOH Ethics in Health Research(3) document 
highlights the following when considering informed consent for genetic research: 
 “Provision to the donor of full information about the purposes of the 
sampling and/or an outline of the research proposal; 
 The donor’s consent to the use of the sample in the experiment being 
planned; 
 The donor’s consent to storage and future use of the sample for other 
research; 
 Giving donors the assurance that all secondary use of donated tissue 
samples will require approval of an accredited research ethics committee; 
 Reassuring donors that no tests of known clinical value for diagnosing or 
predicting disease on samples can be linked to them without their 
consent; 
 Provision for appropriate and secure storage of tissue samples; 
 Provision for and maintenance of appropriate and secure systems to 
ensure confidentiality and privacy in the recording, storage and release of 
data; 
 Accountability in the care and usage of samples; 
 A statement of the duration of sample storage.”(3) 
 
Institutional responsibility is highlighted, and includes the following: “It is the 
responsibility of the institution or organization at which research involving human 
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tissue samples is conducted, to ensure that all uses of human tissue samples are in 
accordance with the consent given by the donors.”(3) Proper records must also be 
kept. Samples that are not needed anymore should be disposed of “safely and 
sensitively.”(3) This does not mention what needs to be done if the donor has died. 
The DOH guideline document(3) specifies that a research ethics committee should 
oversee this functioning of human tissue repositories, especially the process of 
informed consent. 
The issue of informed consent for genetic research is dealt with in great detail in the 
DOH document. The following relevant issues are specified: 
 Participants may refuse consent without prejudice, and do not need to feel 
obliged to participate to serve the interests of his/her family; 
 If genetic samples are de-identified, participants will not be able to receive 
results. If not de-identified, the participant has a choice on whether to receive 
results that relate to the individual; 
 If the research may have implications for other family members, consent from 
participants for this disclosure will be obtained beforehand;  
 If relatives are required to participate in the research, the original participant 
will be consulted first, bearing in mind potential family dynamics and 
relationships; 
 Disposal of genetic material at completion of the research needs to be 
discussed in detail with participants; 
 “Genetic material and information may have uses unrelated to research 
approved by a research ethics committee. Participants should be advised 
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that their material and information will not be released for other uses without 
their consent, unless required by law. If consent is given, the duration of 
storage should be specified. If consent for future use is refused, the genetic 
material and information should be disposed of at the end of the research, 
once the sample storage and record-keeping requirements of good research 
practice have been met”(3). 
 
This is very specific consent, and falls into the domain of multi-layered consent, as 
opposed to the more commonly used blanket consent. 
 
The CIOMS international guidelines have an added comment on informed consent, 
as follows: “renew the informed consent of each subject in long-term studies at pre-
determined intervals, even if there are no changes in the design or objectives of the 
research”(9). This would ensure that participants are still aware of the importance of 
autonomy and informed consent, and would allow a formal setting should they wish 
to withdraw consent. 
 
Waived consent has been mentioned in the general discussion on informed consent 
in this context. The DOH document states that a research ethics committee may 
waive the participants consent, with or without conditions, subject to the following: 




 The justification presented for seeking waiver of consent, including the extent 
to which it is impossible or difficult or intrusive to obtain consent;  
 The proposed arrangements to protect privacy, including the extent to which 
it is possible to de-identify the sample; 
 The extent to which the proposed research poses a risk to the privacy or 
wellbeing of the donor; 
 Whether the research proposal is an extension of, or closely related to, a 
previously approved research project; 
 The possibility of commercial exploitation of derivatives of the sample and 
relevant statutory provisions”(3). 
The MRC document on ethics for medical research(22) and the MRC guidelines for 
genetic research(24) both discuss informed consent in great detail. 
Consent is described as being absolutely essential, and “in the absence of 
compelling reasons to the contrary, written information and consent forms should be 
the norm for health research interventions”(22).  
 
The pre-requisites of consent are as follows: 
 The capacity of a person to consent is described as being someone who is 
legally and factually capable of consenting. 
 Informed consent must include the participants understanding of what they 
are consenting to, and he/she must have full participant autonomy, without 
investigator paternalism (the researcher knows best). Participants must 
61 
 
understand the right to refuse or withdraw, and must give clear, unequivocal, 
free and voluntary comprehensive and revocable consent. 
 Investigators have a duty to fully disclose the following: 
 The exact nature of the research in great detail; 
 The nature, scope and possible consequences; 
 The anticipated benefits and possible disadvantages; 
 The foreseeable prognosis, additional risks, dangers and 
complications; 
 The possible personal benefits, which may include financial. 
 Genetic research also requires consent for genetic counseling, which has its 
own specific detailed guidelines. 
 
The MRC guideline for genetic research states the following: 
“Informed consent is an accepted norm in the clinician-patient relationship, implying 
the patient’s knowledge of the major characteristics of their medical disorder, an 
understanding of the test or procedure they are to undergo, the limitations of the 
test or procedure, and the possible consequence of their participation in the test or 
procedure followed by their agreement, or not, to undergo the test or procedure. 
This term includes a right on the part of the participants or patients to be informed of 
risks not actually related to the medical impact of the test or procedure, including 
possible socio-economic consequences of an unfavourable test result, such as loss 
of health or life insurance, refusal of employment, discrimination by schools, 
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adoption agencies, etc. should where applicable, be included under the description 
of risks”(24). 
This illustrates the extent of the detail of the risks and possible consequences that 
participants need to consider, prior to consenting to genetic research. 
 
And finally, The HPCSA General Ethical Guidelines for Health Researchers(23) 
discusses the health researchers’ duties to research participants. Included in these 
duties are: 
 Acting in the best interests of research participants;  
 Respect for research participants 
 Research participant confidentiality; 
 Impartiality and justice; 
 Informed consent. 
 
Informed consent is broken down into many components which have been covered 
by the DOH guidelines(3) and both MRC guideline documents(22, 24). Issues that 
are highlighted are the following: 
 Research participants need sufficient information in a suitable language; 
 The well-being of the participants rests with the researcher; 
 Consent must not be coerced or obtained under duress; 
 Information must not be purposefully withheld; 
 Informed consent should be regarded as an ongoing process, giving the 
participants opportunities to withdraw; 
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 Consent must be adequately documented. 
 
In conclusion, we have come a long way since Stoffberg v Elliot(25) and Castell v 
de Greef(29) from the point of view of informed consent. Our South African 
Constitution, the National Health Act and all of the national research guidelines and 
regulations go a long way in protecting vulnerable research participants, particularly 
















INVESTIGATION OF CONSENT DOCUMENTS IN CLINICAL TRIALS 
WITH A GENETIC COMPONENT EVALUATED DURING ONE YEAR. 
 
4.1 Objective 
To carry out a pilot study retrospectively analyzing the type of consent given by 
adults participating in genetic research.  
The reason for a pilot study is that this research has not been done previously, and 
it was necessary to obtain a “feel” for the type of information available in order to 
guide future research. 
 
4.2 Methodology 
4.2.1 Study design 
This study was a retrospective descriptive study of sponsored clinical trial 
applications submitted to the Human Research Ethics Committee (Medical) of the 
University of the Witwatersrand [HREC(Medical)] through the Wits Health 
Consortium (WHC). The WHC is a not for profit organisation and a private 
company, wholly owned by the University of the Witwatersrand. The Ethics 
Secretariat at the WHC manages sponsored clinical trial applications for the HREC 




4.2.2 Ethical considerations 
4.2.2.1 Ethics approval 
This study was approved by the Human Research Ethics Committee of the 
University of the Witwatersrand before data were collected.  (Appendix A) 
 
4.2.2.2 Postgraduate committee approval 
This study was approved by the Postgraduate Committee of the Faculty of Health 
Sciences of the University of the Witwatersrand.  (Appendix B) 
 
4.2.2.3 Declaration of Helsinki 
The research was conducted in keeping with the principles as described in the 
Declaration of Helsinki (2013)(18). 
 
4.2.3 Study site 
The study site was the Wits Health Consortium (WHC). The records were those in 
which patients had been asked to participate in genetic research, in particular, the 
documentation on informed consent. The data are stored in a database purpose-
designed by the WHC for the management of clinical trials. 
 
4.2.4 Study population 
The study population comprised all patients who participated in genetic research 
through the Wits Health Consortium during the specific dates in section 4.2.5.  
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4.2.5 Study period 
The records that were studied were from clinical trials that were initiated between 
the 1st January 2013 and the 31st December 2013. 
 
4.2.6 Sample population  
No patient records were studied. The research protocols for studies that had been 
submitted to the Wits Health Consortium were used. 
 
4.2.7 Exclusion criteria 
Studies that were not approved by the Wits Research Ethics Committee were 
excluded, as well as studies involving paediatric patients. All other studies were 
included.  
 
4.2.8 Data Collection 
After discussion with a supervisor and a statistical advisor (Emeritus Professor LP 
Fatti) the following data were collected: (Appendix C) 
 Protocol number 
 Genetic sample, site of storage and the length of time of storage 
 Specific mention of data sharing 
 Type of consent 
 Complexity of language used for consent 
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 Benefit sharing 
 
4.2.9 Data analysis 




The study was self-funded. 
 
4.3 Results 
4.3.1 General comments 
Ninety-two protocols were studied. 30 had an adult storage component, of which 19 
were to be subjected to some form of genetic study. 
The balance (sixty-two) were either studies that were rejected or withdrawn, 
involved children, or had no storage component for genetic research. 
What was striking about the protocols with a storage component (with or without 
genetic experimentation), was the very large variation in the types of consent, the 
documentation, complexity of language used, and the components of the genetic 
research. These components varied from actual DNA research, to sample storage, 
with often limited information on the site of repository and length of storage time, as 
well as the actual genetic research. It occasionally included the issue of data 
sharing, but this too was inconsistent. 
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4.3.2 Results: Descriptive statistics on the protocols for 2013 
These will be discussed under the following headings: 
1. A breakdown of all of the protocols studied. 
2. Details on the protocols with a storage component. 
3. The types of informed consent.  
The following table illustrates all of the protocols from 2013 that were used for this 
study. The sample storage column indicates the number of the stored samples that 
were used for genetic testing in brackets. 
 

















January 5 3 (2) 1 1 0 
February 9 7 (3) 1 0 1 
March 10 3 (3) 5 1 1 
April 8 1 (0) 6 1 0 
May 9 1 (1) 6 2 0 
June 9 3 (1) 3 1 2 
July 2 1 (1) 0 1 0 
August 13 3 (2) 6 3 1 
September 4 0 (0) 2 2 0 
October 9 4 (2) 2 2 1 
November 14 4 (4) 7 3 0 




4.3.2.1 The breakdown of all of the protocols  
As can be extrapolated from table 4.1, sixty-two (67%) of the protocols submitted to 
the Wits Health Consortium in 2013 did not include a storage component, and 
therefore were not involved in genetic research. The breakdown is as follows: 
 Thirty-nine (42%) protocols involved research in adults where no samples 
were to be stored, and no genetic research was to be performed. 
 Seventeen (18%) involved research in children and were therefore excluded. 
 Six (7%) of the protocols submitted were either declined or withdrawn. 
 
4.3.2.2 Details on the protocols with a storage component. 
The 30 protocols (listed in table 4.2) with a storage component were studied in 
detail. They were given a study number, and an attempt was made to elucidate the 
following: 
 The type of sample for storage, an indication of whether genetic testing 
would be done, the site of storage, and the length of time of storage; 
 Whether there was specific mention of data sharing; 
 The complexity of the English language used for the consent documentation; 
 The type of consent that was required for the genetic research component. 





Table 4.2 Protocols with a storage component, indicating whether genetic 
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4.3.2.3 The type of sample for storage, whether genetic testing would be done, 
the site of storage and the length of time of storage 
In 29 of the 30 samples (96%), blood was one of the components that was to be 
stored. Other samples included cells, tissue, bone marrow, urine, stool and tumour. 
Nineteen of the 30 samples (63%) were to be subjected to genetic testing, which in 
most protocols was not very specific and not described in detail. 
 
The storage site was not always specified, and usually involved Europe and/or the 
United States of America (USA). Some of the protocols that did not specify the site 
stated the following: “storage at a laboratory designated by the sponsor”. The 
breakdown is as follows: 
 Nine of the 30 in the USA; 
 Eight of the 30 in a country in Europe; 
 Four of the 30 would be stored in more than one country; 
 In 9 of the 30 protocols, the site of storage was not indicated. 
The length of storage time ranged from one year to 20 years, and was not specified 
in 12 of the protocols (40%). In one protocol the samples would be destroyed 
immediately after testing. 
 
4.3.2.4 Specific mention of data sharing 
Data sharing was specified in only four (13%) of the protocols. Having said that, 




4.3.2.5 The complexity of English language used for obtaining consent 
Simple English (at the level of comprehension of school grade 10) was used in nine 
of the 30 (30%) protocols. This is of concern when one takes into account that 
South African lay persons are supposedly giving informed consent for sample 
storage, with or without genetic testing, and may not have understood the intricacies 
of the consent that was required of them. This is particularly so if the discussion was 
not in a language of their choice. It would appear that the various pharmaceutical 
companies who sponsor the research, are given a specific format for the way in 
which their consent forms are worded, depending on the country of origin of the 
head office of the company. This results in inconsistency when taking into account 
all of the principles specified in our various laws and regulations, as well as the way 
in which the informed consent document is worded. 
 
4.3.3 Type of consent  
As was previously discussed in chapter 3, the commonly used types of consent for 
sample storage with or without genetic research are as follows: 
 Broad or blanket consent, which would allow the use of a sample for genetic 
research in general, including future unspecified projects. New consent 
would then be necessary if the next research project differs from the wide 
ambit of the original. From the perspective of human dignity, the case for 
broad consent “explicitly acknowledges the existential importance of being 
able to decide on morally meaningful matters for oneself. In addition, the 
belief that one can contribute to the good of others plays a role”(39). 
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 Multilayered or tiered consent, with secondary use as another alternative. In 
this case a comprehensive consent form is used, allowing the genetic sample 
owner to choose from a number of options in advance, as well as specific 
research domains. The latter is covered by a “secondary use statement”. 
This form of consent has been described as costly and complex. 
 Waived consent, which has been introduced by some Research Ethics 
Committees (REC) where re-contact consent has been impossible. Strict 
criteria need to be applied in these circumstances in order to prevent abuse. 
 
Eleven out of the 30 protocols (37%) that involved sample storage had specific 
consent for the tests that were to be carried out. The balance had blanket consent, 
except for two, which had tiered consent. Many of the consent documents stated 
that they would approach the Wits Human Research Ethics Committee (REC) 
should they wish to perform further studies. Many of these statements were very 
vague, and did not fulfil the category of waived consent. The impression created by 
some of the statements in these protocols is that they were documented because of 
the standing orders from the Wits Heath Consortium and the Wits Human Research 
Ethics Committee (REC), and not because it was in the patients’ best interests.  
The other area of concern is that the consent taken should be dynamic, with the 
ability to withdraw it at any stage. This was often mentioned in the forms, but the 
mechanism by which consent could be withdrawn was often not stated, and not 




4.3.4 Other consent issues 
4.3.4.1 Confidentiality, anonymity and identifiability were all dealt with to some 
extent in all of the protocols, and were in keeping with current recommendations of 
protection of identifiers and coding.  
 
4.3.4.2 Benefit sharing in the form of financial benefits was discussed and clarified 
by some of the protocols. However, many were ambiguous. Benefit sharing from the 
data point of view was not mentioned by most of the protocols, and is a violation of 
the respect for patients’ autonomy. Only four out of 30 protocols (13%) specified 
that data would be shared, and the sharing was usually all over the world. One 
protocol mentioned that data would be kept, but did not comment on whether it 
would be shared. 
 
4.4 Conclusion 
This study investigated the protocols that were submitted to the Wits Health 
Consortium during 2013. A small number (30%) fulfilled the criteria of sample 
storage, with or without genetic testing. 
 
The Problem Statement laid out in chapter one of this research report asks the 
following: 
“Is the consent obtained from adult patients for genetic research informed, morally 





If one examines the recommendations on informed consent in many of the 
International guidelines, the DOH guidelines(3) and both MRC guideline 
documents(22, 24), many of the protocols examined in this study fell short with 
respect to the following: 
 Research participants requiring sufficient information in a language which 
they are able to fully comprehend. 
 Full disclosure of precisely how the sample/s would be handled, where they 
would be sent, and who would have access to them. The attitude of many of 
the research companies appeared to be that once they have the samples, 
the patient has absolutely no say, ever again. 
 Informed consent being a dynamic ongoing process, enabling the patient to 
withdraw consent at any stage.  
 Whether data would be stored and for how long, and whether it would be 
shared. 
 
As McGuire et al stated in their article on DNA data sharing: research participants’ 
perspectives(43): “Current genomic research policy calls for public data release with 
specific consent for data sharing. Because most clinical investigators are not 
responsible for and do not anticipate data broadcast, few include information about 







DISCUSSION and RECOMMENDATIONS 
 
5.1 General comments 
The pilot study conducted for this research report has demonstrated that there is 
substantial room for improvement when drawing up protocols which have a genetic 
research component necessitating detailed informed consent from participants. 
One of the important factors when examining the protocols is that there is no 
standardization. Many of the companies involved are multinationals, who have their 
own format when drawing up protocols. Whilst this may be acceptable for the 
informed consent for the contract research being performed, it is not recommended 
for the informed consent being obtained for the storage of samples and the genetic 
component. 
 
5.2 Specific comments 
As discussed in chapter 2, the DOH Ethics in Health Research(3) document 
highlights the following when considering informed consent for genetic research: 
 “Provision to the donor of full information about the purposes of the 
sampling and/or an outline of the research proposal; 




 The donor’s consent to storage and future use of the sample for other 
research; 
 Giving donors the assurance that all secondary use of donated tissue 
samples will require approval of an accredited research ethics committee; 
 Reassuring donors that no tests of known clinical value for diagnosing or 
predicting disease on samples can be linked to them without their 
consent; 
 Provision for appropriate and secure storage of tissue samples; 
 Provision for and maintenance of appropriate and secure systems to 
ensure confidentiality and privacy in the recording, storage and release of 
data; 
 Accountability in the care and usage of samples; 
 A statement of the duration of sample storage.”(3) 
My findings will be interpreted in this context. 
 
5.2.1 Specific recommendations 
The results of this study have illustrated that many of these duties are only partially 
fulfilled in many of the protocols studied. In order to address these inconsistencies 
the following recommendations are made: 
1. The informed consent process and paperwork need to be standardised for all 
protocols in which samples will be stored and genetic research performed. 
This standardization will ensure that the following requirements are not 
omitted, as occurred in some of the protocols that were studied: 
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 The site of storage; 
 The length of time of storage; 
 Details of the sample/s being stored; 
 Specific details of the genetic research to be performed. 
 
2. Detailed attention needs to be paid to the language used and the complexity 
of the terminology used when obtaining informed consent for sample storage 
and genetic testing. The South African MRC documents specify that research 
participants should receive the information in a language which they are able 
to fully comprehend. I recommend that the genetic consent portion of the 
WHC protocols needs to be translated when necessary and where 
appropriate, and where suitable funds are available. This would enable the 
ethical requirement of full disclosure to be achieved, and would be acting in 
the best interests of the research participants. In addition, it would allow 
detailed information on the commercial aspect of patenting and cell lines to 
be shared with the research participants. If translated versions are not 
available for practical or financial reasons, then a translator should be 
present. 
 
3. The type of informed consent used in the various protocols is of concern. It is 
recommended that this too is standardised, to either specific consent, as 
occurred in some of the protocols, or dynamic consent, as has been 
described in chapter 3 of this research report. These two types of consent 
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lend themselves to continued involvement by the research participant in the 
study, as well as facilitating withdrawal of consent, which is the participant’s 
ethical right. Where this type of consent is not possible, then multilayered or 
tiered consent is recommended as the next best form of ethical consent. In 
an interesting article in the European Journal of Human Genetics(44), 
Steinsbekk et al have recommended broad or blanket consent, with dynamic 
consent modifications, which, in time, may be worth considering. 
 
4. Data sharing is one of the important issues in genetic consent which may 
undermine the ethical principles of autonomy, human dignity and the 
supremacy of consent. Whilst this was not an initial objective in this study, it 
was decided that it is such an important ethical issue, that this study would 
document whether this was specifically dealt with in the consent 
documentation. As has been described in chapter 4, very few protocols and 
consent documents described data storage, and data sharing. Hence it was 
assumed that informed consent was not obtained for data sharing from the 
research participants in most of the WHC protocols that were studied. It is 
therefore recommended that consent for data sharing is incorporated into the 
consent documentation as a matter of urgency.  
McGuire et al performed a study looking at different types of consent for data 
sharing(45). They documented the willingness of participants to release data 
either publicly or in a restricted fashion, before and after being debriefed 
about the details of the study. After the debrief sessions, many participants 
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withdrew consent for public release, preferring the option of restricted release 
of their anonymized data. 
This appears to indicate that we currently underestimate the importance of 
data sharing to our research participants. Further research in the field is 
necessary to determine which path should be followed. 
 
5.3 Conclusion 
It is strongly recommended that changes are implemented to the way in which 
informed consent is obtained from research participants involved in genetic 
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Appendix C Data capture form 
 
MSC (Med) Health Law and Bioethics record review 
 
Date Protocol No Genetic sample Type of consent 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 
 
